This inventor holds 13 USPTO granted patents. Top assignee: Ciba-Geigy Corporation. Active years: 1977-1994.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1977-1994
Title: Jaroslav Kalvoda: Innovator in Pharmaceutical Chemistry
Introduction
Jaroslav Kalvoda is a notable inventor based in Binningen, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds and processes. With a total of 13 patents to his name, Kalvoda's work has had a considerable impact on the industry.
Latest Patents
Kalvoda's latest patents include a process for the preparation of optically active acyloxyazetidinones. This innovative method allows for the synthesis of compounds of the formula ##STR1##, where R.sub.1 is hydrogen or lower alkyl, R.sub.2 is hydrogen or a hydroxyl protective group R.sub.2', and R.sub.3 is substituted or unsubstituted phenyl or lower alkyl. The process is accomplished in three stages from readily accessible .beta.-lactam starting materials. Another significant patent involves the synthesis of beta-lactam compounds, which describes an improved process for preparing compounds of formula ##STR1## or their salts, starting from specific precursor compounds.
Career Highlights
Kalvoda has been associated with Ciba-Geigy Corporation, a prominent player in the pharmaceutical industry. His work has focused on enhancing the efficiency and effectiveness of chemical processes, contributing to advancements in drug development.
Collaborations
Throughout his career, Kalvoda has collaborated with esteemed colleagues such as Ernst Hungerbuhler and Michel Biollaz. These partnerships have fostered innovation and have been instrumental in the successful development of his patented processes.
Conclusion
Jaroslav Kalvoda's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the field. His work continues to influence the development of new therapeutic compounds and processes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile